Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Scinai Immunotherapeutics's Debt-to-Equity or its related term are showing as below:
SCNI'
s Debt-to-Equity Range Over the Past 10 Years
Min: -35.93 Med: -0.88 Max: 29.52
Current: 0.3
During the past 13 years, the highest Debt-to-Equity Ratio of Scinai Immunotherapeutics was 29.52. The lowest was -35.93. And the median was -0.88.
SCNI's Debt-to-Equity is ranked worse than 63.29% of 967
companies
in the Biotechnology industry
Industry Median: 0.16
vs SCNI: 0.30
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Scinai Immunotherapeutics Debt-to-Equity Related Terms
Scinai Immunotherapeutics Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SCNI vs ABPO, RMTG, EVFM: Debt-to-Equity Comparison
For the Biotechnology subindustry, Scinai Immunotherapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scinai Immunotherapeutics Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Scinai Immunotherapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Scinai Immunotherapeutics's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scinai Immunotherapeutics (SCNI) has a Debt-to-Equity of 0.30 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Scinai Immunotherapeutics and its competitors. According to the industry distribution chart, Scinai Immunotherapeutics ranks #612 out of 967 companies in the Biotechnology industry, placing it in the top 63.3%.
Is Scinai Immunotherapeutics' Debt-to-Equity too high?
Scinai Immunotherapeutics' current Debt-to-Equity is 0.30. The Biotechnology industry median Debt-to-Equity is 0.16. Scinai Immunotherapeutics' value of 0.30 is 87.5% above this industry median. Based on the distribution chart, Scinai Immunotherapeutics ranks #612 out of 967 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Scinai Immunotherapeutics has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Scinai Immunotherapeutics' Debt-to-Equity compare to ABPO and RMTG?
According to the Biotechnology industry distribution chart, Scinai Immunotherapeutics ranks #612 out of 967 companies for Debt-to-Equity. This places Scinai Immunotherapeutics in the lower half of its industry. The industry median Debt-to-Equity is 0.16. Scinai Immunotherapeutics' value of 0.30 is 87.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 967 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Scinai Immunotherapeutics's current Debt-to-Equity of 0.30 is 87.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Scinai Immunotherapeutics and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scinai Immunotherapeutics's current Debt-to-Equity is 0.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scinai Immunotherapeutics stock overvalued right now?
Scinai Immunotherapeutics (SCNI) has a current Debt-to-Equity of 0.30. The current Debt-to-Equity is 0.30 and 87.5% above the Biotechnology industry median of 0.16. Scinai Immunotherapeutics' overall GF Score™ is 20/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Scinai Immunotherapeutics (SCNI), the current Debt-to-Equity is 0.30 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units: (i) Scinai R&D, focused on the development of therapeutics in inflammation and immunology, and (ii) the contract development and manufacturing organization (CDMO) business. The CDMO business provides integrated development and manufacturing services to small and emerging biotech companies, supporting clients from early-stage development through clinical-stage production.
20GF Score
Get the complete analysis for SCNI
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SCNI has been successfully added to your 
